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The incidence and severity of Clostridium difﬁcileeassociated disease (CDAD) within the general population
has risen dramatically over the past decade, yet little data are available from hematopoietic stem cell
transplantation (HSCT) centers. In the present study, we performed a chart review of 822 consecutive
autologous and allogeneic HCST recipients treated at Northwestern Memorial Hospital between 2004 and
2008 to determine the incidence of CDAD at our institution. Variables including age, sex, diagnosis,
chemotherapy regimen, transplantation type, microbial colonization, coinfections, diet, antibiotic use, neu-
tropenic fever, comorbid conditions, time to engraftment, growth factor administration, and occurrence of
graft-versus-host disease were assessed as potential risk factors for the development of CDAD. Eighty-ﬁve
CDAD cases (10.3%) were identiﬁed. Bivariate analysis revealed a signiﬁcant association between CDAD and
neutropenic fever, administration of a neutropenic diet, ciproﬂoxacin and aztreonam use and duration of
therapy, vancomycin and aztreonam use and duration of therapy, receipt of an allogeneic transplantation,
bacterial coinfection, and vancomycin-resistant Entereococcus faecium (VRE) colonization. Cox regression
analysis identiﬁed the following as factors associated with the development of CDAD: age >60 years, allo-
geneic transplantation, and prior VRE colonization. Allogeneic recipients with CDAD experienced increased
higher rates of grades II to IV gastrointestinal graft-versus-host disease and nonrelapse mortality. A risk
stratiﬁcation model was developed to identify HSCT recipients at different levels of risk. With an incidence
>10%, CDAD is a signiﬁcant infectious complication of stem cell transplantation.
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Clostridium difﬁcileeassociated disease (CDAD) is linked
to signiﬁcant morbidity and mortality. An increase in the
incidence and severity of CDAD has been observed both in
the community and in hospitalized patients over the past
10 years, with outbreaks of a new hypervirulent CDAD
(BI/NAP-1) strain increasingly reported across North America
and Western Europe over the last 5 years. Currently, CDAD is
the most common source of hospital-acquired diarrhea.
Gastrointestinal (GI) surgery, antibiotic use, and medical
comorbid states are known to increase the risk for devel-
oping CDAD in the general population [1-4].
The period surrounding hematopoietic stem cell trans-
plantation (HSCT) is accompanied by profound changes
within the GI tract. Prolonged neutropenia, exposure to
prophylactic and empiric antimicrobials, damage to the GI
tract from chemotherapy conditioning regimens, immuno-
suppression, microbial coinfection, suppression of gastric
acid by H2 blockers and proton pump inhibitors, reduced
oral alimentation, and administration of low-microbial diets
change the GI microenvironment, cause diarrhea in most
HSCT recipients, and may predispose patients to develop
CDAD [5,6]. Single-institution epidemiologic studies from
HSCT centers have reported the incidence of CDAD between
5% and 18%; however, most of these studies were conducted
more than a decade ago. Since then, transplantation prac-
tices have evolved (transplantation type, conditioning regi-
mens), along with changes in the spectrum of infectious
microorganisms and new antimicrobial agents used to ﬁghtedgment on page 409.
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We performed a chart review study in 822 consecutive
autologous and allogeneic HSCT recipients treated at
Northwestern Memorial Hospital (NMH) between 2004 and
2008 to determine the incidence of CDAD to analyze patient-,
disease-, and transplantation-speciﬁc characteristics as
potential risk factors associated with the development of
CDAD and to report clinical outcomes. A risk stratiﬁcation
model was formulated to identify patients at the different
levels of risk for developing CDAD.METHODS
Electronic medical records for 822 consecutive HSCT recipients who
underwent their transplantations between August 2004 and August 2008
were used to screen for CDAD. Pharmacy records were used to obtain data
on antibiotic usage. All HSCT recipients underwent their transplantations as
hospital inpatients. CDAD was deﬁned as the occurrence of diarrhea and
either a positive result from a laboratory stool assay for C. difﬁcile toxin A or
B or a positive culture from a toxigenic C. difﬁcile strain. Both culture and
toxin assay were performed in all patients with diarrhea tested for
C. difﬁcile.
Patients were screened for C. difﬁcile infection 30 days before HSCT
hospital admission and upon hospital discharge. Patients who experienced
CDAD were followed as outpatients for 100 days posttransplantation to
determine clinical outcomes, infection recurrence, and the development of
GI graft-versus-host disease (GVHD). All HSCT recipients received prophy-
lactic acyclovir, a triazole antifungal, and a ﬂuoroquinolone antibiotic unless
they were receiving alternate treatment for a prior infection. All patients
received a proton pump inhibitor during hospital admission.
Allogeneic HSCT recipients (allo-HSCT) remained on the same prophy-
lactic antimicrobial regimen throughout day þ100 after HSCT, whereas
autologous HSCT recipients (auto-HSCT) received acyclovir once daily upon
hospital discharge. All positive bacterial and fungal cultures were used for
analysis, except single coagulase-negative Staphylococcus cultures and
vancomycin-resistant Entereococcus faecium (VRE) broncheoalveolar speci-
mens. Rectal VRE surveillance cultures were performed weekly during
hospital admission.Transplantation.
Table 2
Risk Factor Analysis for Clostridium difﬁcile Infection
Characteristic CDAD n (%) Non-CDAD
n (%)
P Value
HSCT recipients 85 737
Time to CDAD post-HSCT,
day (range)
8 (4-45)
Time to engraftment 12 11
Male 47 (56) 434 (59) .55
Age, yr (range) 60 (21-74) 56 (18-74) .062
HSCT
Allogeneic 30 (37) 176 (24) .01
Autologous 52 (63) 566 (76) .01
Diagnosis
Myeloma 42 (51) 400 (54) .642
Acute leukemias 16 (19) 126 (17) .54
Non-Hodgkin lymphoma 10 (12) 140 (19) .173
Conditioning regimen
High-dose melphalan based 46 (56) 467 (63) .337
BEAM 7 (8) 103 (14) .23
Busulfan and ﬂudarabine/
Cytoxan
14 (17) 117 (16) .751
RIST (MEL 100/m2  Cytoxan) 14 (17) 69 (9) .034
Neutropenic fever 63 (74) 441 (60) .0132
Auto-HSCT 36 (77) 315 (56) .36
Allo-HSCT 27 (77) 126 (74) .84
Neutropenic diet 32 (39) 377 (51) .036
Auto-HSCT 29 (58) 281 (50) .03
Allo-HSCT 25 (71) 71 (42) .0015
VRE-positive surveillance
cultures
31 (35) 143 (19) .0006
Auto-HSCT 18 (33) 101 (18) .0042
Allo-HSCT 13 (36) 42 (28) .141
Microbiologically conﬁrmed
bacterial cultures
37 (42) 155 (21) .0012
Auto-HSCT 16 (.32) 105 (15) .0125
Source of infection
Blood 24 (28) 138 (19) .046
Urine 6 (7) 23 (3) .04
Broncheoalveolar/sputum 9 (11) 13 (2) .001
Antibiotics
Ciproﬂoxacin 79 (93) 688 (93) .99
Ciproﬂoxacin duration 10.47 8.37 .0001
Cefepime 63 (77) 500 (68) .103
Cefepime duration 6.56 5.5 .08
Piperacillin/tazobactam 13 (16) 135 (18) .99
Piperacillin/tazobactam
duration
7.46 5.54 .28
Vancomycin 59 (72) 404 (55) .003
Vancomycin duration 7.46 5.54 .28
Atreonam 18 (21) 99 (14) .0058
Atreonam duration 7.71 4.93 .036
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clinical assessment and endoscopy in the remainder. Due to NMH policy
changes, half the HSCT recipients received a neutropenic diet during neu-
tropenia, whereas the other half did not. The main difference between
a neutropenic and non-neutropenic diet was the allowance of fresh fruits,
nuts, seeds, and vegetables.
Metronidazole 500 mg 3 times daily was given as initial therapy for all
new CDAD cases. Patients who experienced persistent diarrhea or whowere
intolerant to metronidazole were empirically switched to oral vancomycin
125 to 250 mg 4 times daily for a minimum of 10 days or until resolution of
neutropenia and discontinuation of systemic antibiotics. Antibiotic success
was deﬁned as complete abatement of CDAD symptoms or negative
C. difﬁcile follow-up cultures for patients with persistent diarrhea. Molecular
characterization studies of C. difﬁcile isolates were not available for all
patients and thus were not reported.
Statistics
Bivariate analysis was performed using chi-square analysis and Fischer’s
t-test to assess the difference in variables between CDAD and non-CDAD
patients. Cox regression analysis was used to identify risk factors for CDAD
and to create a risk stratiﬁcation model for the development of CDAD. This
study was approved by the NMH Institutional Review Board.
RESULTS
Among the 822 transplantation patients reviewed were
615 autologous and 207 allogeneic transplantation patients.
Diarrhea was reported in 83% of all HSCT cases. Eighty-ﬁve
cases (10.3%) of CDAD were identiﬁed. CDAD was diag-
nosed 8 days (median) after stem cell infusion during the
time when most patients were neutropenic. Five patients
developed CDAD before stem cell infusion. The time to stem
cell engraftment was 1 day longer for patients with CDAD.
Patient demographics are shown in Table 1. No signiﬁcant
differences were observed for sex, diagnosis, or conditioning
regimens between CDAD and non-CDAD HSCT recipients.
The results of bivariate analysis are shown in Table 2.
CDAD occurred signiﬁcantly more often in allogeneic
patients (14.5%) compared with autologous patients (8.5%).
For patients who underwent an allogeneic transplantation,
the incidence of CDAD was similar between patients who
received either a full myeloablative or a reduced-intensity
conditioning regimen. More CDAD patients experienced
febrile neutropenia and were more likely to develop
a microbiologically conﬁrmed infection. The general (non-
neutropenic) diet was associated with a lower, although not
statistically signiﬁcant, risk for CDAD. Patients who were
colonized with VRE (rectal surveillance positive) developedTable 1
Demographics
Characteristic Number
Age yr (range) 58 (18-78)
Men 443
Transplantations 822
Autologous 617
Allogeneic 205
Diagnosis
Myeloma 445
Non-Hodgkin lymphoma 152
Acute myeloid leukemia 130
Hodgkin disease 38
Acute lymphocytic leukemia 14
Myelodysplastic syndrome 8
Chronic lymphocytic leukemia 8
Other 28
Conditioning regimen
High-dose melphalan (200 mg/m2) 513
BEAM 173
Busulfan and ﬂudarabine or Cytoxan 131
Reduced-intensity (MEL 100 mg/m2  Cytoxan) 83
Other 22
Mel indicates Melphalan.
Corticosteroids 14 (17) 104 (14) .505
Allo-HSCT 21 (60) 50 (29) .002
Grades II-IV GI GVHD
(60 days post-HSCT)
10 (28) 19 (11) .0139
Grades II-IV GI GVHD
(100 days post-HSCT)
13 (37) 22 (1) .0024
Overall mortality (auto-HSCT) 2 (2) 16 (2) .99
Overall mortality (allo-HSCT) 5 (6) 13 (2) .178
Overall mortality with grades
II-IV GVHD
10 (29) 17 (10) .0104CDAD more often than those who were VRE negative. CDAD
patients received aztreonam and vancomycinmore often and
were treated with ciproﬂoxacin and vancomycin for a longer
duration of therapy.
CDADwas diagnosed before GI GVHD in 10 of 13 allo-HSCT
recipients (77%). The incidence of acute grades III-IV GI GVHD
was signiﬁcantly higher in CDAD patients 60 and 100 days
posttransplantation. Overall nonrelapsemortalitywas greater
in allo-HSCT recipients with CDAD who developed aGVHD
compared to allo-HSCT recipients who developed aGVHD
without CDAD. There was no difference in overall mortality
between CDAD and non-CDAD auto-HSCT recipients.
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Figure 1. CDAD risk stratiﬁcation. Low: Age 60 þ no VRE
colonization þ autograft. Medium: Age>60 þ no VRE colonization þ autograft.
Age 60 þ VRE colonization or allograft. High: All others. P < .001.
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of an allo-HSCT, and VRE colonization to be independently
signiﬁcant factors associated with CDAD (P < .001). Based on
the three risk factors identiﬁed by regression analysis, a risk
stratiﬁcation model was developed demonstrating widely
disparate incidences of CDAD (Figure 1). Risk ratios were as
follows: age >60, 1.4639 (range, 1.1828 to 1.8117); allo-HSCT,
1.9072 (range, 1.2174 to 2.9880); and VRE colonization,
1.6501 (range, 1.0526 to 2.5869). The incidence of CDAD was
>20% in patients with all three risk factors.
Most CDAD patients (87%) were successfully treated with
metronidazole 500 mg orally three times daily. Oral vanco-
mycin was substituted in 17 patients (20%) because of
intolerance to metronidazole or for persistent diarrhea
despite negative follow-up C. difﬁcile cultures. Clinically,
C. difﬁcile was eradicated from the stool in all patients as
determined by repeat negative cultures in patients with
persistent diarrhea or formation of a normal stool (repeat
cultures not performed). CDAD recurred in 10 patients (12%)
a median of 37 days (range, 7 to 92 days) after initial CDAD
infection. Only one patient experienced more than one
recurrence of CDAD. C. difﬁcile A or B toxinwas negative in 22
patients (27%) when the toxigenic C. difﬁcile stool culturewas
positive.
The number of transplantation cases performed at NMH
during the study period increased >40% (2004, 180 trans-
plantations per year; 2008, 250 transplantations per year).
The number of CDAD cases was relatively constant each
month (median, 1.7 cases) over the entire 4-year study
period. Predictably, a move to a new hospital facility resulted
in the complete disappearance of all CDAD cases for the ﬁrstTable 3
CDAD Studies in HSCT Recipients from 2000-Present
Author (year) Study Period Transplant Type Number
Chakrabarti [7] (2000) 1994-99 Allogeneic 75
Avery [8] (2000) na Autologous 80
Van Kraaj [9] (2000) 1995-96 Autologous/allogeneic 47
Tomblyn [10] (2002) 1998-2000 Autologous/allogeneic 119
Jillella [11] (2003) 1997-2001 Autologous 54
Arango [12] (2006) 1996-2001 Autologous 242
Chopra [13] (2011) 2005-6 Autologous/allogeneic 3613 months after the new facility opened. Thereafter, CDAD
cases increased steadily over the subsequent months to rates
similar to those observed in the older facility.
DISCUSSION
CDAD is the most common cause of hospital-acquired
diarrhea and has been increasing in incidence over the last
10 years. Community-acquired CDAD is emerging as
a previously unrecognized entity that is frequently under-
diagnosed. Antibiotic and proton pump inhibitor overuse,
older age, chemotherapy, and outbreaks of a newly recog-
nized hypervirulent C. difﬁcile NAP-1 strain have been iden-
tiﬁed as causes for the increased incidence of CDAD [4-6].
The period surrounding HSCT is replete with medical
(chemotherapy, antimicrobials, immunosuppression) and
environmental (dietary changes and restrictions, lateral
transmission of disease via health care workers) factors that
predispose HSCT recipients to diarrhea. Diarrhea is almost
universally observed after stem cell transplantation.
C. difﬁcile has been recognized as a cause of diarrhea in HSCT
recipients for many years.
The overall incidence of CDAD during our 4-year study
period was 10.3%. CDAD rates within our institution have
increased from 6.4%, as previously reported in 2000, to 8.5%
over the past 10 years after autologous transplantation.
CDAD rates were signiﬁcantly higher in allogeneic recipients.
Table 3 summarizes retrospective studies conducted from
HSCT centers since 2000. For most studies, patient accrual
was completed more than 10 years ago. Variable CDAD
incidence rates, generally between 1% to 12% for auto- and
allo-HSCT recipients, were observed [7-13]. The most
recently published epidemiologic study reported by Chopra
et al. [13], conducted during the same time period as the
present study, observed CDAD rates similar to our results.
The incidence of CDAD was reported to be several times
greater than the general population and signiﬁcantly higher
than patients treated for cancer. Collectively, the most
current studies report higher CDAD rates compared with
earlier studies and suggest CDAD rates are increasing within
the stem cell population, paralleling the rise in CDAD
observed within the general population.
A limitation of previously reported CDAD studies con-
ducted within the HSCT population has been the inability to
identify unique risk factors associated with the development
of CDAD, perhaps due to small sample sizes. The present
study identiﬁed 3 risk factors associated with the develop-
ment of CDAD by multivariate regression analysis.
Age>60 yearswas identiﬁed as a risk factor for CDADafter
HSCT. This may be a direct result of the increasing number of
patients> 60 years old undergoing autologous and allogeneic
transplantations over the past decade. Data from the Center
for International Blood andMarrow Transplant Research [14]Incidence of CDAD (%) Risk Factors Identiﬁed
13 >High-grade GVHD, nonrelapse mortality
5 None
Auto ¼ 4
Allo ¼ 0
None
Auto ¼ 7
Allo ¼ 0
None
6.7 None
15.5 Antibiotics
Auto ¼ 8
Allo ¼ 18
None
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formed in patients aged >60 years has more than doubled
between 1993 to 2003 and 2004 to 2008. Autologous trans-
plantations have also increased signiﬁcantly [14]. Data from
discharged hospital patients within the nontransplantation
setting have also reported a several fold higher age-adjusted
rate of clostridium difﬁcile infection among persons older
than 64 years [15].
Many comorbid conditions increase with age, and these
conditions increase the likelihood for altered chemotherapy
distribution, metabolism, and excretion, leading to increased
toxicity. For many conditioning regimens, mucositis along
the entire GI tract is the dose-limiting toxicity. Chemother-
apeutic agents alone have been shown to be independent
risk factors for the development of clostridium difﬁcile
infection. Changes to the intestinal microbiota after chemo-
therapy alone are similar to those observed in CDAD patients
after antibiotic administration. These changes have been
associated with increasing inﬂammation and permeability
and reduction in the protective mucosal layer, epithelial
repair, and immune responsiveness. The role of excessive
damage to the GI tract caused by chemotherapy and its
association with infection in older patients requires further
investigation [16-22].
Receipt of an allogeneic transplantation was observed to
be an independent risk factor for the development of CDAD.
A number of factors could be responsible for the pathogen-
esis of CDAD in this population. Allo-HSCT recipients typi-
cally experience a longer period of neutropenia before stem
cell engraftment, increasing the exposure to broad-spectrum
antibiotics, which are known risk factors for the develop-
ment of CDAD. Additionally, longer hospital admissions place
patients at an increased risk for transmission of nosocomial
infection.
Patients receiving immunosuppressants are at increased
risk for developing infections. Some evidence suggests these
agents may be directly linked to CDAD. Experimentally, in
mice not exposed to antibiotics, cyclosporine administration
was shown to lead to the development of mild to moderate
CDAD [23]. Clinically, a retrospective review of liver trans-
plantation recipients who received immunosuppressant
agents similar to those used during HSCT, yet typically
receiving signiﬁcantly less antibiotic use, reported CDAD
rates similar to our study, indirectly suggesting a possible
link between immunosuppression and CDAD [24].
We identiﬁed VRE rectal colonization as a newly recog-
nized risk factor for the development of CDAD in HSCT
recipients. VRE colonization rates were similar among allo-
geneic and autologous recipients. Recent laboratory and
clinical studies have suggested a link between VRE and
C. difﬁcile colonization and infection. Experimentally,
a murine model has shown VRE cultures administered exog-
enously after the administration of antibiotics almost
completely displaced the normalmicrobiota of the intestines,
allowing for the growth of antibiotic-resistant microbes and
Clostridium ssp. This effect lasted for several weeks. The
authors also described similar dramatic changes to the
intestinal microbiota in two allo-HSCT recipients associated
with endogenous intestinal VRE stool culture predominance.
These changes were not seen in three control patients who
did not develop VRE bacteremia [25].
Additional evidence for a link between VRE colonization
or infection and C. difﬁcile infection was reported in a small
cohort study (n ¼ 10) of patients with acute leukemia. The
correlation between CDAD and VRE was observed in thereverse order of our ﬁndings: C. difﬁcile infection and treat-
ment increased the likelihood of VRE infection. All patients in
that study had prior VRE colonization [26]. Comparative
retrospective trials from patients within the general pop-
ulation from acute care facilities or nursing homes have also
identiﬁed a relationship between VRE infection or coloniza-
tion and coinfection with C. difﬁcile, both associated with
antibiotic administration [27,28]. Finally, the results of our
prior study, which questioned the role of a lowmicrobial diet
during HSCT, identiﬁed a higher incidence of C. difﬁcile
infection in patients and positive VRE surveillance cultures
[29]. Collectively, the data suggest VRE colonization or
infection and C. difﬁcile infection together occur more
frequently than previously recognized.
An association between ciproﬂoxacin, vancomycin, and
aztreonam use and duration of therapy and the development
of CDAD was observed. Our results are consistent with
previously reported results of antibiotic-associated CDAD
from studies both within the general population and in HSCT
recipients. Antibiotic-associated CDAD has long been impli-
cated with virtually all antibiotics, although differences in
associated incidence rates exist that depend on the spectrum
of activity and pharmacokinetic properties [30]. Attempting
to reduce antibiotic-induced CDAD through restriction of
ﬂuoroquinolone antibiotic prophylaxis during HSCT is
problematic, as recent evidence-based guidelines state
ﬂouroquinolone prophylaxis be considered for high-risk
patients with expected durations of prolonged and profound
neutropenia [31]. The risk for developing CDAD appears to be
even greater with the concomitant use of antibiotics and
proton pump inhibitors [32].
Our results show CDAD patients are more likely to
develop grades II-IV GI GVHD both 60 and 100 days post-
HSCT. These results are consistent with a published case-
control (37 CDAD patients and 67 control subjects) study
by Dubberke et al. [33] that reported a signiﬁcant increase in
new-onset GVHD, new-onset severe GVHD, and new-onset
gut GVHD associated with CDAD 180 days post-HCST. Also
observed were signiﬁcantly higher rates of bloodstream
infections after diagnosis with CDAD and increased non-
relapse mortality rates in CDAD patients [33]. The results
establish CDAD as one of the many causes associated with
morbidity and nonrelapse mortality in HSCT recipients.
Despite a 40% increase in the number of HSCT trans-
plantationsperformedeachyearover the4-year studyperiod,
the monthly CDAD rate remained constant throughout the
study period. Patient isolation, glove and gown precautions,
and handwashing with soap were maintained equally
throughout the study period. C. difﬁcile is a transmissible
nosocomial pathogen, and one could speculate that height-
ened awareness and improved infection control might have
been responsible for curtailing horizontal transmission of
CDAD. Implementation of an infection control program is
essential for preventing transmission of CDAD.
Most CDAD cases completely resolvedwithmetronidazole
treatment. Patients whowere empirically deemed treatment
failures or intolerant to metronidazole were successfully
salvaged with oral vancomycin treatment. CDAD recurrence
was lowand similar to recurrence rates reported from studies
publishedwithin thegeneral population. Publishedevidence-
based guidelines from the Infectious Diseases Society of
America and the Society for Healthcare Epidemiology of
America recommend oral vancomycin therapy as initial
treatment for patients at high risk (age >64 years, elevated
white blood cell count and serum creatinine levels) for the
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to a recent survey of transplantation centers (n ¼ 34)
regarding initial drug therapy for the treatment of CDAD
indicated most institutions (74%) still prescribe metronida-
zole as front-line drug therapy (personal communication,
Steven Triﬁlio, Northwestern Memorial Hospital, December
20, 2011). Prospective studies are needed to determine
whether the unique serious GI toxicities encountered
during stem cell transplantation warrant similar antibiotic
recommendations.
The rate of false-negative C. difﬁcile toxin A or B assay
results demonstrate a lack of sensitivity for this assay and the
need to conﬁrm C. difﬁcile in stool culture, especially in
patients with persistent diarrhea. We believe the develop-
ment of the risk stratiﬁcationmodel provided in Figure 1 will
assist practitioners in critical clinical decision-making path-
ways. Patients at highest risk for the development of CDAD
may beneﬁt from increased VRE surveillance, minimizing
antibiotics known to promote the development of CDAD, and
heightened environmental and isolation precautions that
may reduce horizontal transmission of CDAD.
With an overall incidence >10%, CDAD is a signiﬁcant
source of infectious complications within the HSCT setting.
Based on patient characteristics and interventions, the risk
ranges from 6% to 20%. Identiﬁcation and correction of
reversible risk factors could potentially reduce the incidence
of CDAD.
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